[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sab Biotherapeutics Inc (SABS)

Sab Biotherapeutics Inc (SABS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 177,309
  • Shares Outstanding, K 50,951
  • Annual Sales, $ 0 K
  • Annual Income, $ 13,270 K
  • EBIT $ -49 M
  • EBITDA $ -46 M
  • 60-Month Beta 0.60
  • Price/Sales N/A
  • Price/Cash Flow 10.33
  • Price/Book 1.11

Options Overview Details

View History
  • Implied Volatility 251.77% (+27.93%)
  • Historical Volatility 43.19%
  • IV Percentile 15%
  • IV Rank 16.35%
  • IV High 958.92% on 03/23/26
  • IV Low 113.60% on 04/22/26
  • Expected Move (DTE 15) 0.57 (15.95%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 186
  • Put/Call OI Ratio 3.45
  • Today's Open Interest 3,531
  • Open Int (30-Day) 2,854
  • Expected Range 3.00 to 4.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.16
  • Number of Estimates 2
  • High Estimate $-0.12
  • Low Estimate $-0.20
  • Prior Year $-0.56
  • Growth Rate Est. (year over year) +71.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.41 +3.08%
on 04/29/26
4.08 -13.85%
on 04/15/26
-0.26 (-7.01%)
since 03/30/26
3-Month
3.41 +3.08%
on 04/29/26
5.15 -31.75%
on 03/12/26
-0.87 (-19.93%)
since 01/30/26
52-Week
1.53 +129.74%
on 05/02/25
6.60 -46.74%
on 07/21/25
+1.82 (+106.76%)
since 04/30/25

Most Recent Stories

More News
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142

GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (Nasdaq: SABS , SAB BIO) to support...

EBS : 8.15 (+2.00%)
SABS : 3.65 (+4.89%)
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder profile concomitant with T cell exhaustion T1D participants receiving...

SABSW : 0.0161 (+5.23%)
SABS : 3.65 (+4.89%)
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress

MIAMI, April 15, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0161 (+5.23%)
SABS : 3.65 (+4.89%)
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0161 (+5.23%)
SABS : 3.65 (+4.89%)
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0161 (+5.23%)
SABS : 3.65 (+4.89%)
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0161 (+5.23%)
SABS : 3.65 (+4.89%)
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10,...

SABSW : 0.0161 (+5.23%)
SABS : 3.65 (+4.89%)
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027...

SABSW : 0.0161 (+5.23%)
SABS : 3.65 (+4.89%)
SAB BIO to Participate in Upcoming Investor Conferences

MIAMI, March 02, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:  SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0161 (+5.23%)
SABS : 3.65 (+4.89%)
SAB BIO to Participate in Upcoming Investor Conferences

MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0161 (+5.23%)
SABS : 3.65 (+4.89%)

Business Summary

SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB Biotherapeutics Inc., formerly known as Big Cypress...

See More

Key Turning Points

3rd Resistance Point 3.73
2nd Resistance Point 3.65
1st Resistance Point 3.57
Last Price 3.65
1st Support Level 3.40
2nd Support Level 3.32
3rd Support Level 3.24

See More

52-Week High 6.60
Fibonacci 61.8% 4.66
Fibonacci 50% 4.07
Last Price 3.65
Fibonacci 38.2% 3.47
52-Week Low 1.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.